Hypoglycemia: Still the limiting factor in the glycemic management of diabetes

Endocrine Practice

Volumn 14, Issue 6, 2008, Pages 750-756

  Cryer, Philip E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; GLUCAGON; INSULIN;

ADRENERGIC SYSTEM; AUTONOMIC DYSFUNCTION; DIABETES MELLITUS; EXERCISE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REGULATORY MECHANISM; REVIEW; SLEEP; BLOOD; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIA; RISK FACTORS;

EID: 64749110344     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.14.6.750     Document Type: Review

References (52)

1. Cryer PE. Diverse causes of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2004;350: 2272-2279.
2. Towler DA, Havlin CE, Craft S, Cryer PE. Mechanism of awareness of hypoglycemia: perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes. 1993;42:1791-1798.
3. DeRosa MA, Cryer PE. Hypoglycemia and the sympathoadrenal system: neurogenic symptoms are largely the result of sympathetic neural, rather than adrenomedullary, activation. Am J Physiol Endocrinol Metab. 2004;287:E32-E41.
4. Cryer PE. Hypoglycemia, functional brain failure, and brain death. J Clin Invest. 2007;117:868-870.
5. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus [published correction appears in Ann Intern Med. 2007;147:887]. Ann Intern Med. 2007; 147:386-399.
6. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140-1147.
7. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes; a progressive disease [published correction appears in Diabetes. 1996;45:1655]. Diabetes. 1995;44:1249-1258.
8. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med. 1998;128:165-175.
9. Hepburn DA, MacLeod KM, Pell AC, Scougal IJ, Frier BM. Frequency and symptoms of hypoglycaemia experienced by patients with type 2 diabetes treated with insulin. Diabet Med. 1993;10:231-237.
10. Donnelly LA, Morris AD, Frier BM, et al (DARTS/ MEMO Collaboration). Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population based study. Diabet Med. 2005;22: 749-755.
11. Holstein A, Plaschke A, Egberts EH. Clinical characterisation of severe hypoglycaemia-a prospective population-based study. Exp Clin Endocrinol Diabetes. 2003;111: 364-369.
12. Leese GP, Wang J, Broomhall J, et al (DARTS/MEMO Collaboration). Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26:1176-1180.
13. Cryer PE. The prevention and correction of hypoglycemia. In: Jefferson LS, Cherrington AD, eds. Handbook of Physiology. Section 7, The Endocrine System. Vol II, The Endocrine Pancreas and Regulation of Metabolism. New York, NY: Oxford University Press, 2001: 1057-1092.
14. Raju B, Cryer PE. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. Diabetes. 2005;54:757-764.
15. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemiaassociated autonomic failure in insulin-dependent diabetes mellitus: recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest. 1993;91:819-828.
16. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724-733.
17. White NH, Skor DA, Cryer PE, Levandoski LA, Bier DM, Santiago JV. Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med. 1983;308:485-491.
18. Bolli GB, De Feo P, De Cosmo S, et al. A reliable and reproducible test for adequate glucose counterregulation in type 1 diabetes mellitus. Diabetes. 1984;33:732-737.
19. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type 1 diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17:697-703.
20. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with shortterm IDDM. Diabetes. 1993;42:1683-1689.
21. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet. 1994;344:283-287.
22. Fanelli C, Pampanelli S, Epifano L, et al. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM [published correction appears in Diabetologia. 1995;38:254]. Diabetologia. 1994;37:1265-1276.
23. Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes. 1994;43:1426-1434.
24. Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure and its component syndromes in diabetes. Diabetes. 2005;54:3592-3601.
25. Cryer PE. Mechanisms of sympathoadrenal failure and hypoglycemia in diabetes. J Clin Invest. 2006;116:1470-1473.
26. Arbelaez AM, Powers WJ, Videen TO, Price JL, Cryer PE. Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure. Diabetes. 2008;57:470-475.
27. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902-1912.
28. DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med. 1991;90:450-459.
29. Fukuda M, Tanaka A, Tahara Y, et al. Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes. 1988;37: 81-88.
30. Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46:271-286.
31. Mühlhauser I, Overmann H, Bender R, Bott U, Berger M. Risk factors of severe hypoglycaemia in adult patients with type 1 diabetes-a prospective population based study. Diabetologia. 1998;41:1274-1282.
32. Allen C, LeCaire T, Palta M, Daniels K, Meredith M, D'Alessio DJ (Wisconsin Diabetes Registry Project). Risk factors for frequent and severe hypoglycemia in type 1 diabetes. Diabetes Care. 2001;24:1878-1881.
33. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care. 2003;26:832-836.
34. Wright AD, Cull CA, MacLeod KM, Holman RR (UKPDS Group). Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS 73. J Diabetes Complications. 2006;20:395-401.
35. Lüddeke HJ, Sreenan S, Aczel S, et al (PREDICTIVE Study Group). PREDICTIVE-a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab. 2007;9:428-434.
36. Veneman T, Mitrakou A, Mokan M, Cryer P, Gerich J. Induction of hypoglycemia unawareness by asymptomatic nocturnal hypoglycemia. Diabetes. 1993;42:1233-1237.
37. Fanelli CG, Paramore DS, Hershey T, et al. Impact of nocturnal hypoglycemia on hypoglycemic cognitive dysfunction in type 1 diabetes. Diabetes. 1998;47:1920-1927.
38. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
39. Reichard P, Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes. 1994;43:313-317.
40. Egger M, Davey Smith G, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med. 1997;14:919-928.
41. Hirsch IB. Insulin analogues. N Engl J Med. 2005;352: 174-183.
42. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes. Cochrane Database Syst Rev. 2007;18:CD005613.
43. Gough SC. A review of human and analogue insulin trials. Diabet Res Clin Pract. 2007;77:1-15.
44. Hirsch IB, Bode BW, Garg S, et al (Insulin Aspart CSII/MDI Comparison Study Group). Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005;28:533-538.
45. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28:1568-1573.
46. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care. 2007;30:389-394.
47. Raju B, Arbelaez AM, Breckenridge SM, Cryer PE. Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. J Clin Endocrinol Metab. 2006;91:2087-2092.
48. Hovorka R. Continuous glucose monitoring and closedloop systems. Diabet Med. 2006;23:1-12.
49. Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006;29:44-50.
50. Briscoe VJ, Ertl AC, Tate DB, Dawling S, Davis SN. Effects of a selective serotonin reuptake inhibitor, fluoxetine, on counter regulatory responses to hypoglycemia in healthy individuals. Diabetes. 2008;57:2453-2460.
51. Wiethop BV, Cryer PE. Alanine and terbutaline in the treatment of hypoglycemia in IDDM. Diabetes Care. 1993; 16:1131-1136.
52. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care. 2001;24:643-645.